Low-dose Morphine Improves Health in COPD Patients With …
Sep 3, 2020 · So, researchers based at the Maastricht University in the Netherlands designed the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Phase 4 study (NCT02429050).It investigated whether regular, low-dose, oral sustained-release morphine improved health in COPD patients with moderate-to-very-severe chronic breathlessness.
1st approved Symbicort generic, Breyna, now available in US
Aug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 and older.
A form of vitamin B3 lowers COPD lung inflammation: Study
Nov 25, 2024 · Assessing inflammation with vitamin B supplement. The University of Copenhagen launched a single-center trial (NCT04990869) at the Respiratory Research Unit at Bispebjerg Hospital in Copenhagen to test nicotinamide riboside against a placebo for its potential as a COPD treatment. The study included 40 adults, mean age 71.9, who had COPD, a history of heavy smoking, and low numbers of ...
Ohtuvayre effective across key patient subgroups: ENHANCE trials
Oct 14, 2024 · In an oral presentation titled “Ensifentrine Improved Lung Function, Symptoms, and Quality of Life Regardless of COPD Severity,” Jessica M. Bon, MD, of Wake Forest University School of Medicine, shared Ohtuvarye’s effects in subgroups of ENHANCE participants stratified by COPD severity. The results showed that Ohtuvaryre led to significant improvements in lung function after three months ...
Dupixent approved in US for adults with poorly controlled COPD
Sep 30, 2024 · In the U.S., the expansion of Dupixent’s label to include COPD brings the number of approved indications up to six, adding to its use as a treatment for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis — all driven in part by type 2 inflammation. “Dupixent has already shown it can revolutionize the treatment paradigm ...
LupinHaler, generic version of Spiriva HandiHaler, available in US
Aug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
Ensifentrine, now Ohtuvayre, wins FDA approval for COPD
Jun 27, 2024 · Verona did not specify the list price for the newly approved therapy. According to an analysis from the Institute for Clinical Economic Review (ICER), Ohtuvayre would meet common cost-effectiveness thresholds if its annual price is between $7,500 and $12,700. ICER is a nonprofit organization whose therapy cost-effectiveness assessments increasingly influence price negotiations and ...
Ohtuvayre (ensifentrine) for COPD | COPD News Today
Jul 9, 2024 · Sold in the U.S./most regions by Verona Pharma, the nonsteroidal medication is designed to improve lung function and ease symptoms in COPD patients. Verona also is developing Ohtuvayre and other inhaled formulations of ensifentrine as a potential treatment for other lung diseases, including asthma and cystic fibrosis.
In COPD with type 2 inflammation, exacerbations lowered with...
Sep 16, 2024 · That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK in a company press release.The study tested mepolizumab against a placebo in adults with COPD and type 2 inflammation, which is marked by high blood counts of eosinophils, a type of immune cell.
Voice changes may enable early detection of COPD exacerbations
Sep 23, 2024 · The voice of people with chronic obstructive pulmonary disease (COPD) becomes more pitched and sounds breathy or hoarse at the early stages of disease exacerbations, which are episodes when symptoms suddenly worsen, according to a pilot study where 28 patients were asked to record their voices every day for about three months.